•  

Posts Tagged: commercialization track record

Xagenic announces second closing of $25.5M Series B financing

TORONTO, July 14, 2014 - Xagenic Inc., a molecular diagnostics company developing the first lab-free molecular diagnostic platform with a 20 minute time-to-result, has announced a second closing of its recently announced Series B financing, bringing the total raised in this round to $25.5 million. In conjunction with this closing, new investor BDC Capital joined as an investor and Dion Madsen, senior managing partner at BDC Capital, will join Xagenic's Board of Directors. From our archives: MaRS Innovation's lead start-up completes $20 million ... Read more

What does MaRS Innovation’s funding extension mean for Toronto’s academic entrepreneurs?

Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. You can read the original post on the MaRS blog. Created in 2008, MaRS Innovation (MI) bridges the chasm between the early-stage technologies emerging from its 16 member institutions and successful startup companies and licensable technologies. By offering early-stage funding in tandem with hands-on management, business development, mentorship and intellectual property protection strategy, MI acts as ... Read more